Is chemoimmunotherapy a game changer in the treatment of locally advanced head and neck squamous cell carcinoma?

Muneyuki Masuda; Ryozaburo Nagata; Hirotaka Hara; Keiji Kuroki; Kuniaki Sato; Fumihide Rikimaru; Satoshi Toh; Yuichiro Higaki

doi:10.1002/ccr3.4793

Is chemoimmunotherapy a game changer in the treatment of locally advanced head and neck squamous cell carcinoma?

Clin Case Rep. 2021 Sep 22;9(9):e04793. doi: 10.1002/ccr3.4793. eCollection 2021 Sep.

Authors

Muneyuki Masuda¹, Ryozaburo Nagata¹, Hirotaka Hara¹, Keiji Kuroki¹, Kuniaki Sato¹, Fumihide Rikimaru¹, Satoshi Toh¹, Yuichiro Higaki¹

Affiliation

¹ Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan.

Abstract

Pembrolizumab and chemotherapy (chemoimmunotherapy) were administered to 2 head and neck squamous cell carcinoma (HNSCC) patients with extremely advanced local tumors and distant metastases with palliative intent. However, they demonstrated strikingly good responses and achieved remission. Expanded application of induction chemoimmunotherapy may be useful for locally advanced HNSCC.

Keywords: advanced head and neck cancer; chemoimmunotherapy; chemotherapy; pembrolizumab.

Publication types

Case Reports